Avid Bioservices Inc (CDMO)

[mskatiescarletohara]

India combo trial is a huge value driver.

They'll need to dose more than 12 patients. The objective is to provide supporting data to the FDA to launch US Phase II cancer studies.

With efficacy data from 12 cancer combo patients and 24 HCV repeat dose patients, investment banks will trip over themselves to give us $40 million at $2.50/share for private placement shares they pump and resell at $5.00 six months later in a secondary offering.

Don't get your hopes up too high on the Phase Ib repeat monotherapy study of non-responders. PPHM's objective is to start combo HCV studies in naive patients with this data.

I don't know a lot of major IB's who will buy lower than 5 PPS.

katie....